| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.00M | 7.00M | 23.39M | 50.93M | 27.94M | 19.54M |
| Gross Profit | 6.36M | 7.00M | 19.38M | 48.83M | 26.22M | -20.16M |
| EBITDA | -382.45M | -326.98M | -130.42M | -60.40M | -48.54M | -33.96M |
| Net Income | -331.03M | -274.48M | -112.96M | -54.81M | -47.53M | -32.27M |
Balance Sheet | ||||||
| Total Assets | 1.04B | 1.12B | 649.32M | 387.97M | 381.35M | 298.27M |
| Cash, Cash Equivalents and Short-Term Investments | 669.74M | 676.32M | 525.11M | 373.15M | 368.06M | 283.58M |
| Total Debt | 26.60M | 19.17M | 2.87M | 3.48M | 5.18M | 6.72M |
| Total Liabilities | 81.62M | 64.94M | 28.23M | 387.97M | 381.35M | 298.27M |
| Stockholders Equity | 959.65M | 1.06B | 621.09M | 349.45M | 301.51M | 198.27M |
Cash Flow | ||||||
| Free Cash Flow | -297.26M | -251.44M | -117.59M | -90.62M | -58.42M | 54.97M |
| Operating Cash Flow | -293.70M | -247.58M | -115.22M | -87.17M | -55.78M | 55.46M |
| Investing Cash Flow | -91.41M | -502.56M | -158.46M | -33.40M | -69.67M | -146.24M |
| Financing Cash Flow | 316.61M | 677.55M | 362.72M | 97.17M | 145.45M | 128.75M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $2.52B | 3.78 | 64.05% | ― | 30.57% | ― | |
56 Neutral | $2.56B | ― | -35.09% | ― | -41.48% | -73.55% | |
55 Neutral | $2.45B | ― | -705.73% | ― | 87.94% | 57.84% | |
54 Neutral | $2.47B | ― | -57.33% | ― | 99.50% | 65.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $3.02B | ― | -41.94% | ― | -82.90% | -155.64% | |
44 Neutral | $2.97B | ― | -134.54% | ― | ― | -25.61% |
On October 17, 2025, IDEAYA Biosciences announced positive median overall survival data from its Phase 1/2 trial of darovasertib combined with Pfizer’s crizotinib for first-line treatment of metastatic uveal melanoma, showing a median OS of 21.1 months. Additionally, on October 20, 2025, IDEAYA presented promising Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma, demonstrating significant tumor shrinkage and eye preservation, with manageable safety profiles.
The most recent analyst rating on (IDYA) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Ideaya Biosciences is conducting a clinical study titled ‘A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer.’ The study aims to assess the safety and effectiveness of IDE849, a potential treatment for tumors expressing DLL3, particularly small cell lung cancer (SCLC). This research is significant as it explores new therapeutic options for a challenging cancer type.
IDEAYA Biosciences, in collaboration with Jiangsu Hengrui Pharmaceuticals, presented promising Phase 1 data for IDE849, a DLL3-targeting TOP1 ADC, at the IASLC 2025 World Conference on Lung Cancer. The trial showed a robust overall response rate and disease control rate in small cell lung cancer patients, with manageable safety profiles across various dose levels. Additionally, IDEAYA shared positive interim results from its Phase 2 trial of darovasertib for primary uveal melanoma, demonstrating significant tumor shrinkage and improved visual outcomes. The company also reported encouraging data from its Phase 1/2 trial of IDE397 combined with Trodelvy in MTAP-deletion urothelial cancer, highlighting a favorable safety profile and notable response rates.
The most recent analyst rating on (IDYA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Ideaya Biosciences is conducting a clinical study titled ‘IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).’ The study aims to evaluate the efficacy of IDE196 combined with Crizotinib compared to standard treatments for patients with metastatic uveal melanoma, a rare eye cancer. This research is significant as it explores a new potential first-line treatment option for this challenging condition.
On August 29, 2025, IDEAYA Biosciences entered into a License Agreement with Les Laboratoires Servier, granting Servier exclusive rights to develop and commercialize darovasertib outside the United States. This agreement includes an upfront payment of $210 million to IDEAYA, with potential additional milestone payments and royalties, extending the company’s cash runway by at least twelve months and funding operations into 2030. The agreement outlines conditions for termination and includes customary transaction provisions.
The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER). The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or with a PD-1 inhibitor, in treating aggressive solid tumors with specific genetic traits.
GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled ‘A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)’. The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or combined with a PD-1 inhibitor, in reducing tumor size in participants with specific genetic tumor characteristics.
IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing transformative therapies for cancer, leveraging expertise in small-molecule drug discovery and antibody-drug conjugates to address molecularly defined solid tumor indications.
Ideaya Biosciences is conducting a clinical study titled (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma. The study aims to evaluate the effectiveness of IDE196 (darovasertib), a drug designed to treat primary uveal melanoma, a rare eye cancer. This study is significant as it explores a potential new treatment option for a condition with limited therapies.